TAMPA, Fla.--(BUSINESS WIRE)--Crosstree, a global leader in health science M&A, recapitalization, and growth financing strategies, has announced that Gordon Ryerson is returning to the firm to launch the company’s newest service: Strategic Value Creation.
With more than 20 years of investment banking and strategic consulting experience specifically within the health science industry, Ryerson will work with companies to develop strategic and actional plans to help them reach a successful outcome downstream.
“Our Strategic Value Creation service is about eliminating guesswork from strategic financial movements in a highly complex market,” said Ryerson. “Before the transaction cycle, Crosstree can help companies assess opportunities and create value using research findings to bring a greater level of certainty.”
The service will also leverage Crosstree’s excellence in distilling granular market data, proprietary research, and tertiary information into practical advice.
“Gordon is deeply ingrained in the health sciences and has an exceptional track record, making him the ideal leader for this new service,” said Shane Senior, co-founder and managing director. “He will be an incredible asset for companies looking to rapidly create value or refine an acquisition strategy.”
The service will allow Crosstree to partner with private equity firms to support strategic investments, grow portfolio companies, and generate superior returns on exit.
Ryerson and other Crosstree principals will share more about the Strategic Value Creation service at the J.P. Morgan Healthcare Conference in San Francisco. The company will be introducing its exclusive Prism Report, the first in a series that reviews the industry’s abrupt transition to targeted and immune therapies and the profound disruption and opportunities created as a result.
Crosstree is a global leader in health science M&A, recapitalization, and growth financing. Leveraging market data, trends, and trusted high-profile relationships, Crosstree helps companies create and articulate value. Focused solely on health sciences for more than a decade, Crosstree has earned a reputation for achieving outstanding results by leading more than 100 successful transactions for clients. Learn more at crosstreecapital.com.